



BPC-157 and TB-500 blend

Results and chromatograms

Sample vial 3, injection 1 | Client report CBI-BPCTB-20-091826

Laboratory Analysis: LAB-CA-02

Laboratory identity and applicable credentials are maintained by Testides and are available to regulatory authorities where required by law.


VIAL PHOTOGRAPH	SAMPLE INFORMATION	ANALYSIS	RUN DETAILS
	Peptide: BPC-157 and TB-500 blend	Method: HPLC-UV	Run date: Sep 23, 2026
	Client ID: CBI-BPCTB-20-091826	Channel: 214 nm	Acquired: 18:55:17 UTC
	Label claim: 20 mg	Integration: Laboratory	Run time: 25 min
	Injection: 10 uL, 214 nm	Identity: Lab-assigned peak	Instrument: HPLC 01

RESULTS AT A GLANCE

PROJECTED AMOUNT 25.36 mg† SUM OF COMPONENTS	HPLC PURITY 97.94% NAMED COMPONENTS, 214 NM*	CONTENT VS. LABEL 126.8% 25.36 MG OF 20 MG CLAIMED	IDENTITY Assigned LAB-ASSIGNED PEAK**
BPC-157 10.86 mg† 108.6% OF 10 MG LABEL		TB-500 14.50 mg† 145.0% OF 10 MG LABEL	

CHROMATOGRAM

Every plotted reading as recorded - overlapping component peaks drawn as peak shapes fitted to the trace



HPLC PURITY (214 NM)

Named components 97.94% Laboratory integration	Integrated peaks 4 Counted in the total	Smallest peak integrated 0.19% Of total area	Recovered chromatogram ±0.02% Area vs. laboratory table
---	--	---	--

Purity is the named component peaks' share of the total peak area the laboratory integrated at 214 nm. The smallest peak it integrated was 0.19% of the total; the laboratory does not state a reporting threshold, so peaks below the ones it integrated are not counted. Integrating the chromatogram recovered from the laboratory's report reproduces its component area to within 0.02%. This result rests on a single injection.

The chromatogram is recovered point for point from the laboratory's report: 211 plotted readings from 8.50 to 12.00 min, joined as drawn; nothing is smoothed or resampled.

* HPLC purity is the named component peaks' share of all peak area the laboratory integrated; every peak is itemised on page 3.

** Identity: the laboratory's processing method names the analyte's peak. The laboratory holds no reference standard for this analyte, so retention time is not compared.

LAB ID: D




BPC-157 and TB-500 blend

Reference comparison and calculation

Sample vial 3, injection 1 | Client report CBI-BPCTB-20-091826


CONCENTRATION CALIBRATION - 214 NM (LABORATORY VALIDATION CURVES)



Component	Peaks	Area %	mg/mL injected	Laboratory curve	Amount	Label share	Content
BPC-157	Peak#1	61.91%	0.5429	BPC-157, HPLC 01	10.86 mg	10 mg	108.6%
TB-500	Peak#2	36.03%	0.7251	TB Fragment, HPLC 01	14.50 mg	10 mg	145.0%

† Amounts use the preparation entered for this vial: 2 mL x 10. Label shares follow the blend's recorded composition: BPC-157 10 mg, TB-500 10 mg. Total 25.36 mg.

NAMED COMPONENT PEAKS



Native plotted readings, nothing smoothed. Overlapping component peaks are drawn and read as peak shapes fitted to the readings, on one baseline under the group, not the laboratory's valley-to-valley integration, which leaves the area beneath the valley in neither peak. Purity is the laboratory's. Components are assigned in the order they elute on the laboratory's method; a component can show as more than one peak.



BPC-157 and TB-500 blend

Definitions, calculation detail, and scope

Sample vial 3, injection 1 | Client report CBI-BPCTB-20-091826

HOW TO READ THIS REPORT

Start with the result on page 1. Pages 2 and 3 show the curve, comparison, and peaks behind it.

01	Recovered chromatogram The laboratory's trace, read back point for point from its report.	02	Integrated peak table Every peak the laboratory integrated, and which one is the analyte.	03	Validation curve Converts the peak area to a concentration for this analyte.
-----------	---	-----------	---	-----------	--

WHAT THE RECOVERED CHROMATOGRAM ADDS

How the chromatogram on this report was obtained

How it was recovered

The laboratory's data system draws the chromatogram in its report as vector data. Every vertex it drew was read back - 211 readings - and both axes were calibrated from the report's own tick marks. Integrating the recovered trace over the laboratory's baselines and peak marks reproduces the area in its peak table to within 0.02%.

What it can and cannot show

It shows every peak, shoulder and baseline the laboratory integrated, at the resolution the laboratory printed. It carries a single wavelength and no UV spectrum, so it cannot reveal a co-eluting compound the way diode-array data can.

Scope: the recovered chromatogram reproduces the laboratory's report. It does not re-measure the sample.

HOW THE PURITY RESULT WAS MEASURED

214 nm area percent, from the laboratory's own integration

The laboratory integrated each peak to its own baseline and named the analyte's peak in its processing method. Purity is that peak's share of the total integrated area; the shares below are recomputed from the areas, and each peak's area is checked against the recovered chromatogram.

$$\text{Purity (\%)} = \text{assigned peak area} / \text{total integrated peak area} \times 100$$

Peak	RT (min)	Area (uV*s)	Area %	Tailing	Plates	Role	Recovered
1	9.463	100,510	1.87	1.34	82,655	impurity	-
2	9.738	10,426	0.19	0.95	119,481	impurity	-
3	9.995	3,330,492	61.91	1.03	52,933	Peak#1 - BPC-157	3,331,243 (+0.02%)
4	10.183	1,938,216	36.03	1.16	98,266	Peak#2 - TB-500	1,937,893 (-0.02%)

Integrated peaks 4 | smallest 0.19% of total | injections 1

Area percent assumes every peak absorbs at 214 nm like the main peak; the analyte's peak is the one the laboratory's method names. Recovered areas are compared for the analyte's peaks of 1% or more.

WHAT THIS REPORT CAN AND CANNOT TELL YOU

The report explains the measurement; it does not decide how a material should be used

Observed evidence

The laboratory's chromatogram, its integration, and its validation curve.

Identity and composition

No definitive identity or absolute purity unless separately supported.

Calculated results

Area-percent purity, concentration, projected amount, and calibration trace.

Safety and performance

No conclusion on safety, sterility, efficacy, fitness for purpose, or suitability.

Method context

Laboratory peak assignment; retention against its reference standard where methods match.

Regulatory status

No regulatory compliance finding, approval, or authorization to manufacture, sell, or use.

This analytical record does not authorize or endorse manufacture, sale, marketing, distribution, or use of the material.